title: Comparative study of calcium-channel blockers on cell proliferation, DNA and collagen syntheses, and EGF receptors of cultured gingival fibroblasts derived from human nifedipine, nicardipine and nisoldipine responders.
abstract: Our previous study indicated that fibroblasts derived from patients reactive to nifedipine might be susceptible to the other calcium-channel blockers (nicardipine, verapamil and diltiazem) in terms of cell proliferation, DNA synthesis, and collagen synthesis. Thus, the present investigation was designed to clarify the cross-reactivity among dihydropyridine calcium-channel blockers (nifedipine, nicardipine, and nisoldipine). Human gingival fibroblasts derived from seven, two, and one patients who developed gingival overgrowth as a result of nifedipine, nicardipine, and nisoldipine medications, respectively, were examined in terms of the effect of calcium-channel blockers (nifedipine, diltiazem, verapamil, and nicardipine) on cell proliferation, DNA synthesis, collagen synthesis, and the number of epidermal growth factor (EGF) receptors. Phenytoin was used as a positive control. With most of the calcium-channel blockers and phenytoin, fibroblasts from patients reactive to nifedipine and nicardipine medications gave a better cell proliferation rate, DNA synthesis, and an increased number of EGF receptors, compared to non-drug-treated control. However, this was not the case for calcium-channel blockers tested in fibroblasts from patients reactive to nisoldipine medication.
authors.affiliation: Department of Pharmacology, Nihon University School of Dentistry at Matsudo, Chiba, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Matsumoto
authors.forename: I
authors.initials: I
authors.lastname: Noji
authors.forename: Y
authors.initials: Y
authors.lastname: Akimoto
authors.forename: A
authors.initials: A
authors.lastname: Fujii
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000494:pharmacology*; D018929:Cell Culture Techniques; D002455:Cell Division / Q000187:drug effects; D003094:Collagen / Q000096:biosynthesis / Q000187:drug effects*; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects*; D004110:Diltiazem / Q000494:pharmacology; D066246:ErbB Receptors / Q000187:drug effects*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects*; D005434:Flow Cytometry; D005881:Gingiva / Q000187:drug effects* / Q000473:pathology; D019214:Gingival Overgrowth / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000009:adverse effects* / Q000494:pharmacology; D009543:Nifedipine / Q000009:adverse effects* / Q000494:pharmacology; D015737:Nisoldipine / Q000009:adverse effects*; D010672:Phenytoin / Q000494:pharmacology; D019275:Radiopharmaceuticals; D013223:Statistics as Topic; D014316:Tritium; D014700:Verapamil / Q000494:pharmacology
chemical_list: D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D019275:Radiopharmaceuticals; D014316:Tritium; D015737:Nisoldipine; D010672:Phenytoin; D003094:Collagen; D004247:DNA; D014700:Verapamil; D009529:Nicardipine; D066246:ErbB Receptors; D004110:Diltiazem; D009543:Nifedipine